OcellO announces strategic outsourcing agreement with Synthon Biopharmaceuticals for compound testing in patient-derived tumour models.
OcellO announced continuation of the collaboration in discovery projects with Synthon Biopharmaceuticals whereby OcellO will provide services for high-content screening in patient-derived in vitro tissue models. OcellO will use panels of patient-derived 3D tumour models for testing of Synthon’s antibody-drug conjugates for its preclinical oncology research programs.
Patient-derived 3D tumour cultures bridge the gap between conventional cell line derivedin vitro models and in vivo models. Furthermore, OcellO’s image-based analysis of 3D tissues provides more detailed insight into the effects of ADCs on tumour tissues compared to conventional growth and killing assays.
| OcellO took part in the LS@W Venture Challenge Fall 2009.
(Its work name in 2009 was: 4DBio).